Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. APRE
stocks logo

APRE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
0.00
-100%
-0.340
-46.88%
0.00
-100%
-0.430
-12.24%
Estimates Revision
The market is revising No Change the revenue expectations for Aprea Therapeutics, Inc. (APRE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -31.61%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-31.61%
In Past 3 Month
Wall Street analysts forecast APRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APRE is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast APRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APRE is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.060
sliders
Low
10.00
Averages
10.00
High
10.00
Current: 1.060
sliders
Low
10.00
Averages
10.00
High
10.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$20
2025-01-15
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$20
2025-01-15
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$20
2024-12-17
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$20
2024-12-17
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Aprea Therapeutics Inc (APRE.O) is -0.70, compared to its 5-year average forward P/E of -1.40. For a more detailed relative valuation and DCF analysis to assess Aprea Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.40
Current PE
-0.70
Overvalued PE
-0.81
Undervalued PE
-1.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.27
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.71
Undervalued EV/EBITDA
-0.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
55.92
Current PS
0.00
Overvalued PS
125.18
Undervalued PS
-13.33
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

APRE News & Events

Events Timeline

(ET)
2025-11-12
08:32:47
Aprea Therapeutics projects funding to last until the fourth quarter of 2026.
select
2025-11-12
08:32:22
Aprea Therapeutics announces Q3 earnings per share of (47c), compared to (64c) in the previous year.
select
2025-10-24 (ET)
2025-10-24
08:33:26
Aprea Therapeutics Shares Progress on ACESOT-1051 Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-24Newsfilter
Aprea Therapeutics Reports Promising Early Results from ACESOT-1051 Trial for WEE1 Kinase Inhibitor APR-1051

  • Clinical Trial Results: In the ongoing Phase 1 ACESOT-1051 trial, 3 out of 4 patients treated with a 100 mg dose of APR-1051 achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies, with disease stabilization linked to specific genetic mutations.

  • Dose Escalation: Following the positive results at the 100 mg level, the trial has progressed to a 150 mg cohort, with no dose-limiting toxicities or unexpected safety issues reported so far.

  • Presentation at Conference: Preliminary findings from the trial will be presented in a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, highlighting the early safety and efficacy of APR-1051.

  • Company Mission: Aprea Therapeutics aims to develop innovative cancer therapies that target cancer cells while minimizing harm to healthy cells, focusing on exploiting vulnerabilities in cancer cell mutations.

[object Object]
Preview
9.0
06-25Newsfilter
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

  • Preclinical and Clinical Findings: Aprea Therapeutics has reported promising preclinical data for APR-1051, a WEE1 inhibitor, showing strong anti-tumor effects in HPV+ head and neck squamous cell carcinoma (HNSCC) models, particularly when combined with anti–PD-1 therapies. Initial clinical results from a Phase 1 trial indicate early disease control in an HPV+ patient.

  • Future Development Plans: The company is progressing with the ACESOT-1051 trial, which includes dose escalation and further evaluation of APR-1051 in combination with checkpoint inhibitors to enhance treatment outcomes for patients with HPV-associated cancers.

[object Object]
Preview
9.5
03-14NASDAQ.COM
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

  • Quarterly Performance: Sutro Biopharma reported a quarterly loss of $0.89 per share, slightly worse than the expected loss of $0.86, with revenues of $14 million exceeding estimates by 34.11%. The company has seen mixed earnings estimate revisions and currently holds a Zacks Rank #3 (Hold).

  • Market Outlook: Despite underperforming the market with a 27.2% decline this year, the stock's future performance will depend on management's commentary and changes in earnings expectations, as well as the overall industry outlook, which is currently favorable within the top 26% of Zacks industries.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aprea Therapeutics Inc (APRE) stock price today?

The current price of APRE is 1.06 USD — it has increased 2.91 % in the last trading day.

arrow icon

What is Aprea Therapeutics Inc (APRE)'s business?

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

arrow icon

What is the price predicton of APRE Stock?

Wall Street analysts forecast APRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APRE is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aprea Therapeutics Inc (APRE)'s revenue for the last quarter?

Aprea Therapeutics Inc revenue for the last quarter amounts to 1.85K USD, decreased -99.48 % YoY.

arrow icon

What is Aprea Therapeutics Inc (APRE)'s earnings per share (EPS) for the last quarter?

Aprea Therapeutics Inc. EPS for the last quarter amounts to -0.47 USD, decreased -26.56 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aprea Therapeutics Inc (APRE)'s fundamentals?

The market is revising No Change the revenue expectations for Aprea Therapeutics, Inc. (APRE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -31.61%.
arrow icon

How many employees does Aprea Therapeutics Inc (APRE). have?

Aprea Therapeutics Inc (APRE) has 8 emplpoyees as of December 05 2025.

arrow icon

What is Aprea Therapeutics Inc (APRE) market cap?

Today APRE has the market capitalization of 6.69M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free